Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eisai to Present Latest Data on Lemborexant at the 36th Annual Sleep 2022 Meeting
Details : DAYVIGO (Lemborexant), an orexin receptor antagonist, is Eisai’s in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2).
Product Name : Dayvigo
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eisai To Present Latest Data Of Lemborexant At 35th Annual Sleep Meeting (SLEEP2021)
Details : DAYVIGO (lemborexant) is a small-molecule compound, discovered and developed by Eisai in-house scientists, that inhibits orexin signaling by binding competitively to both orexin receptor subtypes (orexin receptor 1 and 2).
Product Name : Dayvigo
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 06, 2021
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo® (Lemborexant) in Hong Kong
Details : DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.
Product Name : Dayvigo
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The main presentations from Eisai at this conference include presentations relating to the SUNRISE 2 Phase III clinical trial conducted globally, including sites in Japan.
Product Name : Dayvigo
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eisai to Launch In-House Developed New Anti-insomnia Drug in Japan
Details : DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R).
Product Name : Dayvigo
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 07, 2020
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In clinical studies, DAYVIGO helped some people with insomnia fall asleep faster and stay asleep longer compared to placebo. The effects of DAYVIGO at first use were generally consistent with later timepoints.
Product Name : Dayvigo
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 06, 2020
Lead Product(s) : Lemborexant
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable